Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Seres Therapeutics to Present at J.P. Morgan Healthcare Conference, Highlighting SER-155 Breakthrough Therapy Designation Quiver Quantitative, Inc. - Mon Dec 16, 4:20PM CST

Seres Therapeutics will present at the J.P. Morgan Healthcare Conference, focusing on SER-155's potential to reduce bloodstream infections.Quiver AI SummarySeres Therapeutics, Inc. has announced that CEO...

MCRB : 0.9155 (-0.59%)
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference GlobeNewswire - Mon Dec 16, 6:00AM CST

MCRB : 0.9155 (-0.59%)
Seres Therapeutics Announces FDA Breakthrough Therapy Designation for SER-155 Following Promising Phase 1b Clinical Results Quiver Quantitative, Inc. - Mon Dec 9, 4:18PM CST

The FDA granted SER-155 Breakthrough Therapy designation for reducing bloodstream infections in allo-HSCT patients, supported by promising Phase 1b clinical data.Quiver AI SummarySeres Therapeutics announced...

MCRB : 0.9155 (-0.59%)
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) GlobeNewswire - Mon Dec 9, 6:00AM CST

MCRB : 0.9155 (-0.59%)
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference GlobeNewswire - Fri Nov 22, 6:00AM CST

MCRB : 0.9155 (-0.59%)
Seres Therapeutics: Q3 Earnings Snapshot AP - Wed Nov 13, 6:23AM CST

Seres Therapeutics: Q3 Earnings Snapshot

MCRB : 0.9155 (-0.59%)
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates GlobeNewswire - Wed Nov 13, 6:00AM CST

MCRB : 0.9155 (-0.59%)
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 GlobeNewswire - Wed Nov 6, 6:00AM CST

MCRB : 0.9155 (-0.59%)
Seres Therapeutics: Q2 Earnings Snapshot AP - Tue Aug 13, 6:15AM CDT

Seres Therapeutics: Q2 Earnings Snapshot

MCRB : 0.9155 (-0.59%)
Seres Therapeutics: Q1 Earnings Snapshot AP - Wed May 8, 6:25AM CDT

Seres Therapeutics: Q1 Earnings Snapshot

MCRB : 0.9155 (-0.59%)

Barchart Exclusives

How To Profit From The Latest Corporate Spinoffs: A Guide For Investors In 2025 Barchart - 1 hour ago
How to navigate corporate spinoffs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot